AdaptHealth (NASDAQ:AHCO) Sees Strong Trading Volume – Should You Buy?

Shares of AdaptHealth Corp. (NASDAQ:AHCO) saw unusually-high trading volume on Wednesday . 2,714,947 shares traded hands during mid-day trading, an increase of 86% from the previous session’s volume of 1,462,777 shares.The stock last traded at $6.96 and had previously closed at $6.71.

Key AdaptHealth News

Here are the key news stories impacting AdaptHealth this week:

• Positive Sentiment: AdaptHealth agreed to sell its Diabetes Health business to Cardinal Health for $235 million in cash. Exiting the lower-margin segment could simplify the company’s portfolio, provide liquidity and allow greater focus on sleep and respiratory care. AdaptHealth Q2 revenue rises as net loss widens
• Neutral Sentiment: Second-quarter net revenue was reported at $740.3 million, up 12.7% year over year, with organic growth of 15.9%. However, adjusted EBITDA fell 3.2% to $132 million, showing that revenue growth is not translating into improved profitability. AdaptHealth 2026 Q2 results presentation
• Negative Sentiment: Adjusted earnings missed expectations by a wide margin, while the company posted a substantial net loss, partly because of a $144.2 million goodwill impairment. Revenue also fell well short of analyst estimates in several reports, intensifying concerns about execution and demand. AdaptHealth second-quarter earnings report
• Negative Sentiment: AdaptHealth cut fiscal 2026 revenue guidance to approximately $2.85 billion-$2.89 billion, versus roughly $3.5 billion expected by analysts. New West Coast fixed-price contracts reportedly reduced margins by about $55 million, prompting a $160 million reduction to EBITDA guidance. AdaptHealth fixed-price contracts create risk
• Negative Sentiment: Year-to-date free cash flow turned negative at $48.4 million, compared with positive free cash flow of $73.3 million a year earlier. A law firm also announced an investigation into potential securities-law violations, adding another source of investor uncertainty. AHCO investor alert

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AHCO. Wall Street Zen raised shares of AdaptHealth from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. Jefferies Financial Group upgraded AdaptHealth from a “hold” rating to a “buy” rating and raised their price objective for the company from $11.00 to $13.00 in a research note on Tuesday, July 21st. Weiss Ratings restated a “sell (d)” rating on shares of AdaptHealth in a research note on Friday, May 22nd. UBS Group cut their price objective on AdaptHealth from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Finally, Robert W. Baird set a $10.00 price objective on AdaptHealth in a research note on Wednesday. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.86.

AdaptHealth Stock Performance

The stock has a market capitalization of $934.38 million, a P/E ratio of -11.07, a price-to-earnings-growth ratio of 0.55 and a beta of 1.47. The company has a 50 day simple moving average of $10.22 and a 200-day simple moving average of $10.65. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.92 and a quick ratio of 0.71.

Insider Transactions at AdaptHealth

In other AdaptHealth news, insider Russell E. Schuster III sold 11,275 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $10.06, for a total transaction of $113,426.50. Following the sale, the insider directly owned 136,538 shares of the company’s stock, valued at $1,373,572.28. This represents a 7.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.95% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of AdaptHealth by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 60,495 shares of the company’s stock valued at $656,000 after purchasing an additional 2,564 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in AdaptHealth by 32.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 571,232 shares of the company’s stock worth $6,192,000 after purchasing an additional 139,828 shares in the last quarter. Woodline Partners LP purchased a new stake in AdaptHealth during the 1st quarter worth about $2,851,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in AdaptHealth by 18.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 233,780 shares of the company’s stock worth $2,534,000 after purchasing an additional 35,879 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in AdaptHealth by 1.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 211,769 shares of the company’s stock valued at $1,997,000 after buying an additional 2,718 shares in the last quarter. 82.67% of the stock is currently owned by hedge funds and other institutional investors.

About AdaptHealth

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.